Condition: Lung Cancer · Pulmonary Neoplasm · Sponsor: Rarecells Diagnostics SAS
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
This description comes directly from the study's public registry record.
Monica Tocchi, MD, PhD · 6469331025 · m.tocchi@meditrial.net
Always discuss trial participation with your own doctor first.
| Università Cattolica del Sacro Cuore Gemelli Hospital | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06546007